New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.
What happened
FDA reviewed the company's website, https://nytrt.com/, in September 2026. It found Ofloxacin Eye Drops, Jingzhi Niuhuang Jiedu Pian, and Gui Pi Wan labeled to treat diseases and concluded they are unapproved new drugs with no FDA-approved applications. The website also offers Notoginseng Formula Special Gout Granule; FDA said prior lab analyses of a similarly named product found undeclared drug ingredients, but it had not sampled this variation.
What FDA found
The website labeling shows Ofloxacin Eye Drops, Jingzhi Niuhuang Jiedu Pian, and Gui Pi Wan are intended to treat diseases or affect body function, making them drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128FDA says these products are not generally recognized as safe and effective for their labeled uses, so they are new drugs.
FD&C Act section 201(p), 21 U.S.C. 321(p)No FDA-approved application is in effect for these products.
FD&C Act section 505(a), 21 U.S.C. 355(a)Introducing or delivering these unapproved products for interstate commerce violates the law.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)The company is responsible for ensuring products it sells do not contain undeclared or potentially harmful ingredients; FDA cited prior analyses of a similarly named gout product that found undeclared drug ingredients.
What FDA wants
FDA tells the company to send a written response to FDAAdvisory@fda.hhs.gov within 15 business days of receipt. The response should include steps taken to correct violations, prevent recurrence, related documentation, and reference number 738200.
Who should pay attention
- online sellers of imported Chinese medicines
- brands and distributors of eye drops or herbal drugs
- consumers using unapproved eye or oral drug products
This is a summary. Read the original letter on fda.gov.